NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Sarepta Therapeutics, Inc. SRPT
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.9B
▲ 4.3% vs FY2024
EPS · FY25
$-7.13
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-53.5%
Net margin · FY25
-38.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.9B
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 38 cents on every revenue dollar this year.
Per share
USD -7.13
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-53.5%
Return on equity, FY2025
ROE
Operating margin-37.5%
Net margin-38.3%
Return on assets-19.5%
Each USD of equity lost 53 cents this year.
Returned to shareholders
USD 5.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 5.0M
Share of profit-0.7%
Consecutive raises—
USD 5.0M in buybacks went back to shareholders in a year without profit.
Growth
+32.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+30.2%
+32.5%
+107.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years+32.2%
Change, 10 years+130.0%
The share count grew 32% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.3B
total assets, end of FY2025
Total assetsUSD 3.3B
EquityUSD 1.1B
CashUSD 801.3M
Gross debtUSD 829.0M
Net debtUSD 27.7M
Current ratio2.32×
Net debt stands at 2% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
1.9
1.8
1.1
0.8
0.6
0.5
0.4
0.3
0.2
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
−0.7
0.2
−0.3
−0.5
−0.5
−0.6
−0.7
−0.3
−0.2
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.7
0.3
−0.2
−0.5
−0.4
−0.5
−0.7
−0.3
−0.2
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
·
·
·
·
·
·
·
·
Net income $B
−0.7
0.2
−0.5
−0.7
−0.4
−0.6
−0.7
−0.4
−0.1
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−7.13
2.34
−5.80
−8.03
−5.15
−7.11
−9.71
−5.46
−0.86
−5.49
−5.20
−3.39
−3.31
−5.14
−0.11
−1.74
−0.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−53.5
19.7
−86.2
−107.2
−49.6
−70.1
−77.3
−39.7
−9.0
−101.4
−100.5
−54.9
−60.4
−156.8
−16.4
·
·
Shares out B
0.10
0.10
0.09
0.09
0.09
0.08
0.08
0.07
0.06
0.05
0.05
0.04
0.04
0.03
0.02
0.11
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed